QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 限定条件 发表日期：2020     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 9 作者:  Dai, Meng-di;  Wang, Yue-liang;  Fan, Jun;  Dai, Yang;  Ji, Yin-chun 收藏  |  浏览/下载：33/0  |  提交时间：2021/05/24 receptor tyrosine kinase  FGFR inhibitor  DW14383  antitumor activity   Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report 期刊论文 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10 作者:  Yang, Zi-yan;  Huang, Jia-huan;  Chen, Bo;  Xu, Chun-wei;  Lei, Lei 收藏  |  浏览/下载：28/0  |  提交时间：2020/11/30 salivary duct carcinoma  tyrosine kinase inhibitor  pyrotinib  HER2 positive  targeted   SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 7 作者:  Xia, Zong-jun;  Ji, Yin-chun;  Sun, De-qiao;  Peng, Xia;  Gao, Ying-lei 收藏  |  浏览/下载：78/0  |  提交时间：2020/12/21 ROS1 kinase  ROS1 inhibitor  SAF-189s  lorlatinib  crizotinib resistance  G2032R mutant  NSCLC   Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020 作者:  Wang, Wen-liang;  Jiang, Zong-ru;  Hu, Chen;  Chen, Cheng;  Hu, Zhen-quan 收藏  |  浏览/下载：28/0  |  提交时间：2020/11/26 PGK1  NG52  kinase inhibitor  Warburg effect  glioma   Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 卷号: 41, 期号: 3, 页码: 415-422 作者:  Lai, Meng-zhen;  Song, Pei-ran;  Dou, Dou;  Diao, Yan-yan;  Tong, Lin-jiang 收藏  |  浏览/下载：35/0  |  提交时间：2020/07/01 B cell receptor  Bruton's tyrosine kinase  ibrutinib  small-molecule inhibitor  B cell malignancies   Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent 期刊论文 ACTA PHARMACEUTICA SINICA B, 2020, 卷号: 10 作者:  Jiang, Zongru;  Wang, Li;  Liu, Xuesong;  Chen, Cheng;  Wang, Beilei 收藏  |  浏览/下载：28/0  |  提交时间：2020/11/26 Cancer  VEGFR2 kinase  Kinase inhibitor  Angiogenesis  Inhibitor selectivity   CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study 期刊论文 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10, 页码: 9 作者:  Li, Hailin;  Zhang, Rui;  Wang, Siwen;  Fang, Mengjie;  Zhu, Yongbei 收藏  |  浏览/下载：49/0  |  提交时间：2020/04/07 computed tomography  radiomics  non-small-cell lung cancer  tyrosine kinase inhibitor resistance  anaplastic lymphoma kinase   Discovery of 6 '-chloro-N-methyl-5 '-(phenylsulfonamido)-[3,3 '-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 188 作者:  Liang, Xiaofei;  Jiang, Zongru;  Huang, Zhenghui;  Li, Feng;  Chen, Cheng 收藏  |  浏览/下载：27/0  |  提交时间：2020/11/26 PI4K kinase  Kinase inhibitor  Malaria  Blood stage  Liver stage   discoveryandbiologicalevaluationofn372methoxy44methylpiperazin1ylphenylamino4methyl2oxo2hpyrimido45d13oxazin14hylphenylacrylamideaspotentbrutonstyrosinekinaseinhibitors 期刊论文 actapharmacologicasinica, 2020, 卷号: 41, 期号: 3, 页码: 415 作者:  Lai Mengzhen;  Song Peiran;  Dou Dou;  Diao Yanyan;  Tong Linjiang 收藏  |  浏览/下载：29/0  |  提交时间：2020/07/01 B cell receptor  Bruton’s tyrosine kinase  ibrutinib  small-molecule inhibitor  B cell malignancies